Two Molecules at the Cellular Edge of Aging

The short version

AgeDefy Peptides is a reading digest, not a store. It gathers what the peer-reviewed literature actually says about two molecules that surface repeatedly in serious conversations about cellular aging and healthspan: NAD+ and MOTS-c. One is a coenzyme your cells have always made; the other is a recently discovered peptide that is not even encoded in the usual part of the genome. Both are being studied because they appear to touch something close to the cellular machinery of aging itself — not the surface of the body but the metabolic core.

This digest has one aim: to tell you, with plain language and proper citations, what each molecule was tested on, in which organisms, and what the evidence actually supports. Some of it comes from large clinical trials in humans; some of it is still confined to mice and isolated cells. None of these is a straightforward approved medicine with an established dose. We do not sell anything, do not give medical advice, and do not list a human dose on any page.

What are research peptides?

A peptide is a short chain of amino acids — the same building blocks that make proteins, just far fewer links. Your body is full of them: hormones, signaling molecules, fragments of larger proteins. The ones studied in aging and longevity research are interesting because they can act as precise molecular keys, fitting specific locks on cell surfaces or inside cells, switching particular processes on or off.

A research molecule in this context is one that has been synthesized and studied in the laboratory — in cell cultures, in animals, and in some cases in human clinical trials — but has not necessarily been approved by a regulator as a medicine. "Not approved" covers a wide range: from molecules with robust human trial data that simply haven't completed the full approval process, to early-stage compounds with only preclinical evidence. Where a molecule on this desk derives from something the body already makes naturally, we say so — that lineage is usually the first clue to why it is being studied.

How these two fit into healthspan research

NAD+ and MOTS-c approach cellular aging from different angles, which is exactly what makes reading them together worthwhile.

• NAD+ is the cell's central redox coenzyme — it has been in textbooks for a century. What is newer is the understanding that it also functions as a consumed substrate for signaling enzymes (sirtuins, PARPs, CD38) that govern DNA repair, gene regulation, and inflammation, and that tissue NAD+ declines measurably with age ^[4]. This has generated a wave of clinical testing with precursors such as NMN and NR, with human trial data now accumulating ^[1][2][3].
• MOTS-c is something genuinely unusual: a 16-amino-acid peptide encoded not in the nuclear genome but within the mitochondrial 12S ribosomal RNA gene — the first demonstrated retrograde signal from mitochondria to the nucleus ^[10]. It activates AMPK, improves glucose handling primarily in skeletal muscle, and is induced by exercise. In aged mice it extended physical performance; in humans its circulating levels associate with cardiovascular risk ^[7][9].

Together they represent two strategies aging research is pursuing in parallel: replenishing a metabolic coenzyme that depletes with age, and studying the mitochondria's own molecular language for communicating stress and adaptation. Use the pages to read each one, or compare these peptides side by side.

A note on how this digest reads the literature

AgeDefy Peptides is a cross-referenced literature digest. Each page summarizes the peer-reviewed studies for that molecule, cites them by number, and those numbers link to a single shared references list. Where the evidence is thin, single-lab, or preclinical-only, the page says so in plain terms — because that honesty is the point, not a caveat buried in fine print. This desk describes research findings and the cautions that accompany them; it does not recommend, prescribe, or sell. The goal is a precise, unembellished map of what is known, so the reader can see where the science is solid and where it is still early.